| Name | Title | Contact Details |
|---|
SPOT Sports Animation is a Hammond, IN-based company in the Business Services sector.
Local Government Software Experts BS&A Software provides a tightly integrated system of software products designed specifically for municipalities that demand leading-edge, feature-rich solutions at a value price. We are driven to excellence in all areas of our business by focusing 100% of our efforts on solving customers problems, creating deep and lasting customer relationships through unparalleled customer care, and tenaciously pursuing continued improvement in our software through innovation and customer feedback.
DRiV is a unique $6+ billion dollar global start-up company built from the combined strengths of Tenneco, Federal-Mogul and Ohlins. Our foundation reaches from the Model T to the Model E, and includes 31 of the best known and respected aftermarket brands, including 14 brands 100 years or older. Our global scale and longtime partnerships with the worlds leading manufacturers give DRiV a unique competitive advantage. We are driven to elevate the ride experience through technology and high performance solutions, delivering innovation, quality and unparalleled service to our Aftermarket and OE customers. Our 31,000 team members throughout 25 countries around the world work as one team, driving advancements that help our customers get the most from every vehicle, every ride, every race and every journey.
Redengine Inc is a St. Albert, AB-based company in the Business Services sector.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.